Table S1: Clinical data for enrolled patients (n=18)
Patient
#
Gender
1
2
3
4
5
6
7
M
M
M
M
M
F
F
8
Age on
study
Histology
Metastatic site
70
41
76
64
72
61
50
cc
cc
cc
cc
s
cc
cc
M
56
cc
9
M
69
cc
10
11
12
13
14
15
16
17
M
M
M
M
M
F
F
M
64
53
61
64
42
69
65
47
cc
cc
cc
cc
cc
m
cc
s
18
F
64
cc
Lung, adrenal
Lung
LN
Lung, LN
Lung
Bone
Lung, Adrenal,
LN
Lung, bones,
LN
Lung, liver,
LN
Bone, LN
Lung,LN
Lung,LN
Lung
Lung
Lung,liver
Lung, LN
Skin, LN,
Lung
Bone, LN,
Lung,
Adrenal
MSKCI
/UISS
Best Overall Response
to Treatment
Int/Int
Int/Int
L/Int
Int/Int
L/Int
L/Int
Int/Int
SD:
PR:
SD:
CR:
PD:
PD:
PR:
Stable Disease
Partial Response
Stable Disease
Complete Response
Progressive Disease
Progressive Disease
Partial Response
Int/Int
CR: Complete Response
Int/High
PR: Partial Response
Int/Int
L/L
L/Int
L/High
Int/Int
L/Int
Int/Int
Int/Int
SD:
SD:
PR:
SD:
SD:
SD:
PR:
CR:
Int/Int
PD: Progressive Disease
Stable Disease
Stable Disease
Partial Response
Stable Disease
Stable Disease
Stable Disease
Partial Response
Complete Response
Abbreviations: M= male, F= female, cc= clear cell, s= sarcomatoid, m= medullary, LN= lymph node, MSKCI/UISS=
Memorial Sloan Kettering Cancer Institute/UCLA Integrated Staging System, L= Low, Int= Intermediate
1